📰 Seed Financing News
Page 5 - Seed Financing News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Seed Financing. Real-time updates on events, politics, business and more.
October 13, 2021
/PRNewswire/ -- Tynt Technologies, Inc. (Tynt), a Colorado-based dynamic window company thats engineering the first ever blackout dynamic window, announced it...
October 12, 2021
AceCann Closes $15M in Seed Financing to Produce First Premium, Organic Flower and Extracts for Europe. Funding accelerates development of a state-of-the-art... #AceCann #casaverde #LinceCapital
April 22, 2021
Hits: 137 GAITHERSBURG, MD, USA and GUANGZHOU, China I April 21, 2021 I RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today execution of definitive agreements for a seed round financing of $10 million. RNAimmune is a spin-off entity from Sirnaomics, a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases. Smooth River and Hong Kon...
April 20, 2021
4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics 04/20/2021 | 09:00am EDT Send by mail : Message : 20 April 2021 LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics, Inc. (“Code Bio” or the ”Company”), a next generation gene therapy company pioneering the development of t...
April 20, 2021
4Bio Capital: 4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics 20 April 2021 LONDON & BOSTON - 4BIO Capital ("4BIO" or "the Group"), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics, Inc. ("Code Bio" or the "Company"), a next generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalen...
February 2, 2021
What You Should Know: – Cellino, a Cambridge, MA-based personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the closing of a $16M Seed financing round. The round was co-led by The Engine and Khosla Ventures, with participation from Humboldt Fund and 8VC. – The company’s platform solves a time-consuming, major bottleneck of developing drugs that rely on cell therapy, having to remove stem cells b...